Spicher Pierre, Brazier François, Laville Solène M, Liabeuf Sophie, Kamel Saïd, Culot Maxime, Bodeau Sandra
MP3CV Laboratory, UR7517, Jules Verne University of Picardie, F-80000 Amiens, France.
Blood-Brain Barrier Laboratory (LBHE), UR 2465, University of Artois, F-62300 Lens, France.
Int J Mol Sci. 2025 Jun 30;26(13):6328. doi: 10.3390/ijms26136328.
Chronic kidney disease (CKD) is associated with the systemic accumulation of uremic toxins (UTs) due to impaired renal elimination. Among these, indoxyl sulfate (IS) and p-cresyl sulfate (PCS) are particularly challenging because of their high protein binding and limited removal by dialysis. In addition to renal excretion, the transport of IS and PCS, and their microbiota-derived precursors, indole and p-cresol, across key physiological barriers-the intestinal barrier, blood-brain barrier, and renal proximal tubule-critically influences their distribution and elimination. This review provides an overview of transporter-mediated mechanisms involved in the disposition of IS, PCS, and their microbial precursors, indole and p-cresol. It also examines how these UTs may interact with commonly prescribed drugs in CKD, particularly those that share transporter pathways as substrates or inhibitors. These drug-toxin interactions may influence the pharmacokinetics and toxicity of IS and PCS, but remain poorly characterized and largely overlooked in clinical settings. A better understanding of these processes may guide future efforts to optimize pharmacotherapy and support more informed management of CKD patients, particularly in the context of polypharmacy.
慢性肾脏病(CKD)与因肾脏清除功能受损导致的尿毒症毒素(UTs)全身性蓄积有关。其中,硫酸吲哚酚(IS)和对甲酚硫酸酯(PCS)因其高蛋白结合率以及透析清除有限而特别具有挑战性。除了肾脏排泄外,IS和PCS及其微生物衍生前体吲哚和对甲酚跨越关键生理屏障——肠道屏障、血脑屏障和肾近端小管——的转运,对它们的分布和清除至关重要。本综述概述了参与IS、PCS及其微生物前体吲哚和对甲酚处置的转运体介导机制。它还研究了这些UTs如何与CKD中常用药物相互作用,特别是那些共享转运体途径作为底物或抑制剂的药物。这些药物 - 毒素相互作用可能影响IS和PCS的药代动力学和毒性,但在临床环境中仍特征不明且大多被忽视。更好地理解这些过程可能会指导未来优化药物治疗的努力,并支持对CKD患者进行更明智的管理,特别是在联合用药的情况下。